Drug intelligence / Profile preview

177Lu-P17-088

Development stage: Phase 2
Lead developer: Peking Union Medical College Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

177Lu-P17-088 is a novel radiopharmaceutical therapy designed for the treatment of prostate cancer. It consists of the beta-emitting radioisotope Lutetium-177 (177Lu) conjugated to P17-088, a small molecule ligand that specifically targets Prostate-Specific Membrane Antigen (PSMA), which is highly expressed on the surface of prostate cancer cells. A distinguishing feature of P17-088 is its albumin-binding moiety, which is engineered to extend the drug's circulation time in the blood, thereby potentially increasing tumor uptake and therapeutic efficacy while reducing renal clearance and associated toxicity. The drug is currently being evaluated in clinical trials, primarily for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Other names: 177Lu-labeled P17-088

Targets

PSMA (Prostate-specific membrane antigen)GCPIII (Glutamate carboxypeptidase III)

Beyond the preview

Go deeper on 177Lu-P17-088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-P17-088.

Explore the full profile